Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS AGAINST OFFICERS OF CORMEDIX INC. (NASDAQ: CRMD)

CorMedix Inc. is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the U.S. and internationally. The Company is focused on developing its lead product candidate, DefenCath, a purported novel antibacterial and antifungal solution designed to prevent costly and dangerous catheter-related bloodstream infections ("CRBSIs").

The Company’s common stock is on the Nasdaq Stock Market (“NASDAQ”) under the ticker symbol “CRMD.” Prior to February 2, 2021, the Company’s common stock traded on the NYSE American (“NYSE”) under the same ticker symbol.

As alleged in an underlying securities fraud class action complaint, CorMedix, via certain of its officers, made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, the Complaint alleges Defendants made material misrepresentations concerning the following: (i) deficiencies existed with respect to DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; (ii) in light of the foregoing deficiencies, the FDA was unlikely to approve the DefenCath NDA for CRBSIs in its present form; (iii) Defendants had downplayed the true scope of the deficiencies with DefenCath's manufacturing process and/or at the facility responsible for manufacturing DefenCath; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Lead Plaintiff filed a third amended consolidated Complaint on April 22, 2024.

On June 30, 2025, the court denied Defendants’ motion to dismiss the complaint, determining that Plaintiffs had adequately alleged material misrepresentations; scienter (either (1) a motive and opportunity to commit fraud or (2) "circumstantial evidence of either reckless or conscious behavior”); and loss causation.

Current CorMedix shareholders who have held CorMedix shares since prior to October 16, 2019, can now seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award at no cost to them whatsoever.

If you would like to learn more about this matter, you are encouraged to contact Joshua Grabar at jgrabar@grabarlaw.com or call 267-507-6085.

Attorney Advertising Disclaimer

Join This Action
Name*
First Last
Email Address*
Address*
Street Address City State / Province / Region ZIP / Postal Code
Phone*
Stock Name or Ticker
Number of Shares Purchased
Date(s) Shares Purchased
Purchase Price Per Share
Number of Shares Sold
Date(s) Shares Sold
Sale Price Per Share
Comments
Alternatively, you may upload your transactions using the upload button below or email them to jgrabar@grabarlaw.com. *
File
Drop files here or

Max. file size: 100 MB.
Consent*
By signing and clicking the Submit button below, I hereby execute the Retention Agreement and, upon execution of the Retention Agreement by Grabar Law Office, retain Grabar Law Office to make a demand and bring any ensuing lawsuit on my behalf pursuant to the terms set forth in the Retention Agreement, which is incorporated herein by reference.*
Please sign below using your mouse or touch-pad.*
Signed pursuant to California Civil Code Section 1633.1, et seq. and the Uniform Electronic Transactions Act as adopted by the various states and territories of the United States.
Date of signing: *
Date of Signing:*
MM slash DD slash YYYY
Comments
This field is for validation purposes and should be left unchanged.

Investigations

GRABAR LAW OFFICE INVESTIGATES CLAIMS AGAINST OFFICERS OF CORMEDIX INC. (NASDAQ: CRMD)

Join This Action